This month's review raises a number of important and often difficult ethical and conceptual issues -the ethics of organ donation for lung transplantation, the role of lung transplantation in cystic fibrosis in children, mechanical ventilation in patients with neuromuscular disorders, regulatory control of air pollution and the requirement to undertake RCTs of pharmacological agents in different ethnic groups. It is hoped that consideration of these issues is useful to members of the APSR in their clinical, teaching, research and advocacy roles in the region.
Long-term effects of caffeine therapy for apnea of prematurity
Authors: Schmidt B et al Summary: This study examined the long-term effects of methylxanthine therapy on neurodevelopment and growth in infants treated for apnea of prematurity. 2,006 infants with very low birth weight (500 to 1,250g) were randomised to receive methylxanthine therapy (caffeine) or placebo for as long as treatment for apnea of prematurity was necessary. The primary outcome (death or neurodevelopmental disability at a corrected age of 18 to 21 months) occurred in 40.2% of caffeine vs 46.2% of placebo recipients (odds ratio 0.77, 95% CI 0.64-0.93; p = 0.008). Caffeine reduced the incidence of cerebral palsy and cognitive delay at follow-up compared with placebo, but not rates of death, deafness or blindness. In conclusion, use of caffeine for apnea of prematurity improves the likelihood of survival without neurodevelopmental disability at 18 to 21 months. Comment: A significant neuroprotective effect of caffeine for the treatment of apnea of prematurity in very low birth weight infants. As proposed in the accompanying editorial, we can now conclude that the gains of caffeine therapy outweigh the possible risks (N Engl J Med 2007; 357: 1967-8) . http://content.nejm.org/cgi/content/short /357/19/1893 Reference: N Engl J Med 2007 357:1893 -1902 Caffeine therapy for apnea of prematurity 
Factors associated with lung function decline in patients with non-CF bronchiectasis
Authors: Martinez-Garcia MA et al Summary: This study identified factors associated with lung function decline in adults with stable, non-CF bronchiectasis. 76 adult men and women with bronchiectasis diagnosed by CT scan were included in the study and followed for 24 months. Mean FEV1 decreased by 52.7 mL/year during follow-up. Chronic pseudomonas aeruginosa infection, more frequent severe exacerbations and systemic inflammation were all significant independent factors associated with accelerated decline of lung function. None of the longterm treatment strategies had a significant effect on the decline in FEV1. The investigators concluded that chronic P. aeruginosa colonisation, severe exacerbations and systemic inflammation are independently associated with disease progression in patients with non-CF bronchiectasis. Comment: This study highlights the importance of colonisation with P. aeruginosa as a risk factor for progressive loss of lung function in non-CF bronchiectasis. Novel therapeutic regimes are required if this serious complication of bronchiectasis is to be adequately treated. http://dx.doi.org/10.1378/chest. 07-0490 Reference: Chest 2007; 132:1565-72 
Long-term associations of outdoor air pollution and mortality in Great Britain
Authors: Elliott P et al Summary: This study investigated the link between air pollution and mortality in Great Britain. Annual black smoke (BS) and sulphur dioxide (SO2) concentrations since 1966 were compared with all-cause and cause-specific mortality after adjustment for social deprivation and urban/rural classification. BS and SO2 concentrations were significantly associated with mortality, particularly due to respiratory illness. The adjusted excess relative risk of respiratory mortality was 3.6% per 10 µg/m 3 BS and 13.2% per 10 ppb SO 2 in the period 1982-1998 compared with 19.3% per 10 µg/m 3 BS and 21.7% per 10 ppb SO 2 in the period 1994-1998. The investigators concluded that air pollution has long-term effects on mortality.
Comment: Yet another study showing that exposure to air pollution has long term effects increasing the risk of respiratory related mortality, even at what may be considered as relatively low levels. These findings underlie the importance of public health protection through regulation and control of air pollution. http://dx.doi.org/10. 1136 /thx.2006 .076851 Reference: Thorax 2007 62:1088-94 Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension Authors: Reichenberger F et al Summary: This open-label study investigated the effects of sildenafil (50mg three times daily) in 104 patients with inoperable chronic thromboembolic pulmonary hypertension (WHO functional class II-IV). Treatment with sildenafil reduced pulmonary vascular resistance from 863 dyn·s·cm -5 at baseline to 759 dyn·s·cm -5 after 3 months, and improved 6-minute walking distance from 310m at baseline to 361m after 3 months and 366m after 12 months. The acute haemodynamic effects of a single dose of sildenafil 50mg during initial right heart catheterisation in a subset of 67 patients did not predict long-term outcome.
In conclusion, open-label treatment with sildenafil caused significant functional improvement in patients with inoperable chronic thromboembolic pulmonary hypertension. Comment: Promising data on the use of sildenafil in inoperable CTEPH. The clinical point to note is that the acute effect measured at right heart catheterisation is not a good guide to the long-term response to therapy. A therapeutic trial is preferred in patients who are eligible for this treatment. Note the high dose used of 50mg 3 times daily. http://dx.doi.org/10.1183/09031936.00039007 Reference: Eur Respir J 2007; 30:922-7 , carcinoembryonic antigen, interleukin-6, tumour necrosis factor-a and vascular endothelial growth factor) to discriminate between different pleural effusions. Concentrations of these markers were measured in pleural fluid from patients with malignant (n = 45), parapneumonic (n = 15) and tuberculous (n = 12) pleural effusions. The investigators found that it was possible to discriminate between the 3 groups of patients using the markers, particularly ADA and CRP. A patient with an ADA concentration > 45 µL -1 and a CRP concentration < 4 mg/dL -1 was more likely to have tuberculous pleural effusion, whereas an ADA concentration < 40 µL -1 and a CRP concentration > 6 mg/dL -1 was indicative of parapneumonic pleural effusion, and a CRP concentration < 4 mg/dL -1 was indicative of malignant pleural effusion. It was concluded that ADA and CRP levels might be sufficient for discriminating between the 3 different types of exudative pleural effusion. Comment: An informative study of the use of a number of biological markers to help determine the major cause of exudative pleural effusions. Although ADA and CRP have the greatest discriminative ability, the data do not exclude the usefulness of one or more of the other markers in certain circumstances. http://dx.doi.org/10.1183/09031936.00126306 Reference: Eur Respir J 2007; 30:957-64 Determinants of response to fluticasone propionate and salmeterol/fluticasone propionate (GOAL study) Privacy Policy: APSR will record your email details on a secure database and will not release it to anyone without your prior approval. APSR and you have the right to inspect, update or delete your details at any time.
Disclaimer: This publication is not intended as a replacement for regular medical education but to assist in the process. The reviews are a summarised interpretation of the published study and reflect the opinion of the writer rather than those of the research group or scientific journal. It is suggested readers review the full trial data before forming a final conclusion on its merits.
